We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
-19.51%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$201M
AUM Growth
-$42.4M
(-17%)
Cap. Flow
+$13M
Cap. Flow
% of AUM
6.48%
Top 10 Holdings %
Top 10 Hldgs %
47.8%
Holding
87
New
12
Increased
27
Reduced
14
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$4.12M |
| 2 |
Viking Therapeutics
VKTX
|
+$2.14M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$1.82M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$1.8M |
| 5 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
+$1.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$1.9M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$1.46M |
| 3 |
Novavax
NVAX
|
+$1.32M |
| 4 |
Kura Oncology
KURA
|
+$1.22M |
| 5 |
IMDZ
Immune Design Corp.
IMDZ
|
+$1.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.14% |
| 2 | Miscellaneous | 5.69% |
| 3 | Financials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $25.4M | 12.65% |
181,675
+12,000
| +7% | +$1.82M |
|
2
Stereotaxis
STXS
$145M
| $14.8M | 7.35% |
13,680,554
| – | – |
|
|
SAGE
3
DELISTED
Sage Therapeutics
SAGE
| $9.99M | 4.97% |
104,306
+5,000
| +5% | +$572K |
|
4
AtriCure
ATRC
$2.47B
| $9.75M | 4.85% |
318,729
+25,000
| +9% | +$779K |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $8.93M | 4.44% |
312,119
+6,000
| +2% | +$170K |
|
|
6
iShares Biotechnology ETF
IBB
$10.5B
| $6.26M | 3.11% |
64,900
+38,800
| +149% | +$4.12M |
|
7
argenx
ARGX
$64B
| $5.6M | 2.79% |
58,300
-6,000
| -9% | -$533K |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $5.24M | 2.61% |
143,764
+5,500
| +4% | +$225K |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
| $5.12M | 2.55% |
141,770
+9,000
| +7% | +$422K |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $5M | 2.48% |
92,691
| – | – |
|
11
Ascendis Pharma A/S
ASND
$16.3B
| $4.84M | 2.41% |
77,242
| – | – |
|
12
ProQR Therapeutics
PRQR
$323M
| $4.3M | 2.14% |
272,474
+12,138
| +5% | +$223K |
|
13
DexCom
DXCM
$34.3B
| $4.07M | 2.03% |
136,000
-12,000
| -8% | -$381K |
|
|
ALDR
14
DELISTED
Alder Biopharmaceuticals
ALDR
| $4.06M | 2.02% |
396,013
| – | – |
|
15
Akebia Therapeutics
AKBA
$243M
| $3.96M | 1.97% |
715,538
+89,800
| +14% | +$703K |
|
16
Neurocrine Biosciences
NBIX
$15.7B
| $3.93M | 1.95% |
55,008
+14,000
| +34% | +$1.34M |
|
|
LKFT
17
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $3.82M | 1.9% |
41,609
+2,000
| +5% | +$203K |
|
|
18
BioCryst Pharmaceuticals
BCRX
$2.51B
| $3.75M | 1.86% |
464,415
-187,671
| -29% | -$1.46M |
|
|
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.66M | 1.82% |
93,942
-4,605
| -5% | -$181K |
|
20
Indaptus Therapeutics
INDP
$152M
| $3.49M | 1.74% |
207
-33
| -14% | -$450K |
|
|
LMNX
21
DELISTED
Luminex Corp
LMNX
| $3.2M | 1.59% |
138,391
| – | – |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.96M | 1.47% |
80,000
+50,000
| +167% | +$1.8M |
|
|
FOMX
23
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.9M | 1.44% |
808,000
| – | – |
|
|
BLUE
24
DELISTED
bluebird bio
BLUE
| $2.68M | 1.33% |
2,084
+501
| +32% | +$768K |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $2.62M | 1.3% |
332,511
+38,000
| +13% | +$362K |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, DAFNA Capital Management held 87 positions worth $201M, down 17% from $244M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
DAFNA Capital Management deployed $13M of net new capital in Q4 2018, opening 12 new positions and adding to 27 existing holdings. Its largest new stake was Viking Therapeutics: 179,200 shares worth $1.37M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.9M trimmed.
- DAFNA Capital Management's largest Q4 2018 buy was Viking Therapeutics: 179,200 shares worth $1.37M.
- DAFNA Capital Management added most to iShares Biotechnology ETF in Q4 2018, an estimated $4.12M increase.
- DAFNA Capital Management's biggest Q4 2018 reduction was Immunomedics Inc, cutting an estimated $1.9M.
- DAFNA Capital Management fully exited Novavax in Q4 2018, selling an estimated $1.32M.
- DAFNA Capital Management's ten largest holdings make up 48% of its $201M portfolio in Q4 2018.
- DAFNA Capital Management opened 12 new positions and closed 4 in Q4 2018.
- DAFNA Capital Management's portfolio value fell 17% quarter-over-quarter to $201M.
Based on DAFNA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.